Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concomitant Non-V600E BRAF and KRAS Mutations in Colorectal Carcinoma by Next-Generation Sequencing: A Distinct Subtype.

International journal of surgical pathology - 1 Sept 2024

Srivastava Pallavi, Mishra Sridhar, Shukla Saumya, Sharma Pooja, Husain Nuzhat

Abstract excerpt

The RAS-RAF-MEK-ERK signaling cascade is the most frequently affected signaling pathway in colorectal cancer. BRAFV600E mutations serve as a drug-treatable hotspot and KRAS mutations as a predictor of susceptibility to anti-epidermal growth factor receptor therapy. Concomitant non-V600E BRAF and KRAS mutations may coexist and are rarely reported in the literature. We report a patient of colorectal carcinoma with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Lymphatic Metastasis

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 38086758
DOI: 10.1177/10668969231215425

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concomitant Non-V600E BRAF and KRAS Mutations in Colorectal Carcinoma by Next-Generation Sequencing: A Distinct Subtype.PMID 38086758Read ↗

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision OncologySemantic proximity Read ↗

Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.Semantic proximity Read ↗

BRAF V600E and Non-V600E Mutations in RAS Wild-Type Metastatic Colorectal Cancer: Prognostic and Therapeutic Insights from a Nationwide, Multicenter, Observational Study (J-BROS)Semantic proximity Read ↗

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.Semantic proximity Read ↗

BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series.Semantic proximity Read ↗

Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.Semantic proximity Read ↗

The Coexistence of RAS and BRAF Mutations in Metastatic Colorectal Cancer: A Case Report and Systematic Literature Review.Semantic proximity Read ↗

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?Semantic proximity Read ↗

Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.Semantic proximity Read ↗

Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the LiteratureSemantic proximity Read ↗

BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.